Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.

Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT.

Int J Gynecol Cancer. 2012 Jan;22(1):63-9. doi: 10.1097/IGC.0b013e31822e29aa.

2.

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.

Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ.

J Clin Oncol. 2010 Apr 10;28(11):1936-41. doi: 10.1200/JCO.2009.25.5489. Epub 2010 Mar 8.

3.

Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.

Tournigand C, Louvet C, Molitor JL, Fritel X, Dehni N, Sezeur A, Pigné A, Cady J, Milliez J, de Gramont A.

Gynecol Oncol. 2003 Nov;91(2):341-5.

PMID:
14599864
4.

A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.

Sill MW, Rubinstein L, Litwin S, Yothers G.

Clin Trials. 2012 Aug;9(4):385-95. doi: 10.1177/1740774512450101. Epub 2012 Jul 18.

5.

A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.

Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC.

Clin Cancer Res. 2012 Dec 1;18(23):6509-18. doi: 10.1158/1078-0432.CCR-12-1796. Epub 2012 Oct 2.

6.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

7.
8.

Maintenance chemotherapy for ovarian cancer.

Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D.

Cochrane Database Syst Rev. 2013 Jun 29;(6):CD007414. doi: 10.1002/14651858.CD007414.pub3. Review.

PMID:
23813336
9.

Maintenance chemotherapy for ovarian cancer.

Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007414. doi: 10.1002/14651858.CD007414.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;6:CD007414.

PMID:
20824860
10.

Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.

Pond GR, Abbasi S.

Clin Trials. 2011 Jun;8(3):260-9. doi: 10.1177/1740774511401764. Epub 2011 Apr 20.

PMID:
21511687
11.

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P.

Gynecol Oncol. 2007 Sep;106(3):469-75. Epub 2007 Jul 5.

12.

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.

McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R.

Gynecol Oncol. 2004 Oct;95(1):157-64.

PMID:
15385126
13.

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A.

J Clin Oncol. 2013 Jun 1;31(16):1977-83. doi: 10.1200/JCO.2012.45.6400. Epub 2013 Apr 1.

PMID:
23547079
14.

Mixed response and time-to-event endpoints for multistage single-arm phase II design.

Lai X, Zee BC.

Trials. 2015 Jun 4;16:250. doi: 10.1186/s13063-015-0743-9.

15.

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.

Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators.

Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2.

PMID:
24007819
16.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.

PMID:
23152253
17.

Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.

Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C, Matei D.

Cancer. 2010 Nov 15;116(22):5251-60. doi: 10.1002/cncr.25487.

19.

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P.

Cancer. 2007 Dec 1;110(11):2448-56.

20.

Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.

ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.

Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-19-S5-25. Review.

PMID:
9122738

Supplemental Content

Support Center